Most people on Mounjaro lose between 15% and 21% of their body weight over about 72 weeks, depending on the dose. For someone starting at 250 pounds, that translates to roughly 37 to 52 pounds. These numbers come from the largest clinical trial of the drug, and real-world results vary based on dose, diet, activity level, and individual biology.
Weight Loss by Dose
Mounjaro (tirzepatide) comes in several doses, and the amount you lose scales with how high you go. In the SURMOUNT-1 trial, which followed participants for 72 weeks, average weight loss broke down like this:
- 5 mg dose: 15% of body weight
- 10 mg dose: 19.5% of body weight
- 15 mg dose: 20.9% of body weight
The placebo group, for comparison, lost only about 3%. These are averages, which means some people lost more and some lost less. But the gap between the medication and placebo was consistent and statistically significant across all three doses.
What the Timeline Looks Like
Weight loss on Mounjaro isn’t instant, and the first month is mostly about adjusting to the medication. You start at 2.5 mg, which is a starter dose not really meant to drive significant results on its own. In clinical trials, people lost just under 4% of their body weight in the first four weeks.
The pace picks up as the dose increases. By four months, average weight loss reaches about 11% of starting body weight. By eight months, it’s closer to 20%. After that, the curve flattens and most people are near their maximum loss, which the trials captured at the 72-week mark.
The dose escalation itself takes time. You move up in 2.5 mg increments every four weeks at minimum, stepping through 5 mg, 7.5 mg, 10 mg, 12.5 mg, and up to a maximum of 15 mg. That means reaching the highest dose takes at least 20 weeks if you go all the way up. Many people settle at 10 mg or 12.5 mg depending on how they respond and what side effects they can tolerate.
How Mounjaro Compares to Wegovy
Mounjaro and Wegovy (semaglutide) are the two major weight loss medications right now, and head-to-head data from the SURMOUNT-5 trial gives Mounjaro the edge. In that study, 44% of people on Mounjaro were classified as rapid responders (losing 15% or more of their weight relatively quickly), compared to 21% on Wegovy. The median time to reach 15% weight loss was 36 weeks on Mounjaro versus 52 weeks on Wegovy.
Both rapid responders and slower responders on Mounjaro hit higher weight loss targets than their counterparts on Wegovy. The difference comes down to how the drugs work. Wegovy targets one appetite-related hormone pathway. Mounjaro targets two: it activates both GLP-1 and GIP receptors. That dual action affects appetite suppression through the brain, improves how the body handles insulin, and influences fat storage in ways that a single-target drug doesn’t fully replicate.
Why the Drug Works Differently
Mounjaro’s active ingredient, tirzepatide, mimics two gut hormones your body naturally releases after eating. One of those, GLP-1, is the same hormone that Wegovy and Ozempic target. It slows stomach emptying, signals fullness to the brain, and reduces appetite. The second hormone, GIP, adds something extra. It appears to improve insulin sensitivity through a mechanism that’s independent of weight loss itself, and it acts on fat tissue and metabolic control centers in the brain.
The combination matters because both pathways need to be active for the full appetite-suppressing effect. Research has shown that an intact GIP pathway in the brain is necessary to get the maximum benefit from dual-receptor treatment. In other words, neither hormone alone produces the same result as both working together.
Side Effects That Affect Results
Gastrointestinal side effects are common, especially during dose increases. In clinical trials, up to 18% of patients experienced nausea, up to 17% had diarrhea, and up to 9% reported vomiting. These symptoms tend to be worst in the first few weeks at each new dose and improve as your body adjusts.
Side effects can indirectly affect how much weight you lose. Some people lose weight partly because nausea reduces their appetite beyond what the drug alone would do. Others struggle to stay on the medication or reach higher doses because the GI symptoms are too disruptive. The slow dose escalation schedule exists specifically to minimize these reactions and keep people on track.
What Happens If You Stop
This is the part most people don’t want to hear. A 2025 systematic review published in The BMJ found that people taking newer weight loss medications like Mounjaro and Wegovy regain an estimated 9.9 kg (about 22 pounds) within the first year after stopping. The rate works out to roughly 0.8 kg (1.8 pounds) per month. At that pace, the projected return to baseline weight is about 1.5 years after discontinuation.
That doesn’t mean the medication “didn’t work.” It means obesity is a chronic condition, and these drugs treat it the way blood pressure medication treats hypertension. The effect lasts as long as the treatment does. Some people maintain a portion of their loss through sustained diet and exercise changes made while on the drug, but the biological drive to regain is strong. Most providers frame Mounjaro as a long-term or indefinite treatment for this reason.
Mounjaro vs. Zepbound: Same Drug, Different Label
If you’ve seen Zepbound mentioned alongside Mounjaro, they’re the same active ingredient (tirzepatide) made by the same company. Mounjaro is FDA-approved for type 2 diabetes. Zepbound is FDA-approved specifically for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol. You cannot take both at the same time. The distinction matters mainly for insurance coverage and which indication your provider prescribes it under.